SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss the potential impact of strong October delivery numbers and increased ES8 production. Community members are debating future profitability and potential stock movement, while some compare NIO's position to competitors in the Chinese EV market. Bullish sentiment is building amid anticipation of upcoming earnings reports.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION (ASTER) is trending as the community discusses recent price movements and potential short squeezes, with some speculating about CZ's influence on the token. Bullish sentiment is fueled by perceived strong fundamentals and partnerships, while others express skepticism, citing concerns about market cap and token distribution. Community members are actively discussing potential price targets and trading strategies.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential as a high-reward crypto, citing its significant drop from its all-time high and technologically advanced platform. Some traders are watching for a breakout above key resistance levels, while others remain skeptical, pointing to its past performance. Bullish sentiment revolves around ICP's builders, AI integration, and focus on on-chain functionality.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to an FDA official's controversial LinkedIn post questioning the toxicity and clinical benefit of Lupkynis, which has sparked outrage among investors and led to a sharp decline in the stock price. The community is discussing the potential for legal action against the official and demanding a response from Aurinia's management, while also speculating about the impact on a potential buyout and the company's future prospects. Concerns around the leadership's reaction and the drug's reputation are dominating conversations, with some pointing to past performance as a sign of mismanagement.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending amid discussions about privacy coins and its potential to follow Zcash's price action, with some community members highlighting its limited supply.  Traders are actively discussing technical indicators, potential price targets, and accumulation strategies.  The conversation also includes mentions of Dash's development updates and integrations.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to investor concern over increased spending on AI and a one-time tax charge impacting earnings, overshadowing otherwise positive results. Community discussions revolve around whether the long-term AI investments will pay off, with some fearing a repeat of the Metaverse spending. Despite analyst upgrades, the stock's recent performance has fueled debate about its valuation and future prospects compared to its peers.

Ucore Rare Metals, Inc. Is a technology company, which engages in the business of metal separation products, and services to the mining and mineral extraction industry. Its projects include Bokan-Dotson Ridge Rare Earth Element. The company was founded on October 5, 2006 and is headquartered in Halifax, Canada.

Ucore Rare Metals Inc

Ucore Rare Metals Inc.

Ucore Rare Metals is trending due to renewed focus on establishing a North American rare earth refining capacity, highlighted by government support and strategic partnerships, as the community anticipates significant growth and potential NASDAQ uplisting. Discussions center on Ucore's key role in breaking China's dominance in rare earth processing and the potential for substantial returns as the company progresses towards commercial production. Recent news and upcoming milestones are fueling bullish sentiment, with investors closely watching for further developments in the rare earth sector.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings, with many in the community expressing bullish sentiment and speculating on a potential stock split. Community members are pointing to the company's growing presence in AI and recent government contracts as reasons for optimism, while some caution against the high valuation, suggesting a possible correction after earnings. Discussions also highlight Palantir's partnerships and its potential to disrupt various industries.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as traders weigh the potential impact of economic data and geopolitical events on the biotech sector. Community members are actively discussing technical indicators, potential breakouts, and the influence of broader market sentiment. Some traders are closely watching for news related to tariffs and government policies affecting healthcare.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as the market continues its upward trajectory, defying expectations of a pullback despite concerns of stretched valuations and overbought technical indicators. Community members are discussing the potential for a significant market correction, while others are weighing whether to increase their positions, awaiting a possible trend reversal. Some traders express frustration, feeling trapped as the ETF continues to decline, while remaining hopeful for a large pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria FDA Accepts BioMarin's...

BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +180.00% and -1.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update PR Newswire SAN RAFAEL, Calif., Oct. 27, 2025...

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET BioMarin to Host Third Quarter 2025 Financial Results Conference Call and...

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.78	--	--	N/A
Q3 '25	$0.81	-$0.16	-119.77%	MISSED
Q2 '25	$0.82	$1.23	50.27%	BEAT
Q1 '25	$0.68	$0.95	39.21%	BEAT
Q4 '24	$0.53	$0.64	19.84%	BEAT

BMRN
Biomarin Pharmaceutical Inc. - Registered Shares

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest BMRN News

BMRNBiomarin Pharmaceutical Inc. - Registered Shares